Morgan Bayer

Real-world data demonstrate significant outcome improvements with enfortumab vedotin in patients with unresectable or metastatic urothelial carcinoma.

While lower relative dose intensity of docetaxel was associated with higher rates of G-CSF use and more adverse events, discontinuation rates were low across all groups.

According to real-world data, no survival advantage was seen when comparing 3 frontline CDK4/6 inhibitor combinations in HR-positive, HER2-negative metastatic breast cancer.

The combination of selinexor with ruxolitinib, in both 40mg and 60mg doses, demonstrated encouraging efficacy with a manageable safety profile in patients with myelofibrosis.

Patients with GVHD treated with ruxolitinib plus belumosudil experienced an overall response rate of 55%, which may suggest an interaction between inflammatory pathways.

Resistance training and walking can be beneficial for patients with multiple myeloma.

Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease.